🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Investigational IPF Therapy Developed Using AI, An #ATS 2025 meeting highlight. medcentral.com/pulmonology/in… Idiopathic pulmonary fibrosis (IPF) is a challenging respiratory condition with limited treatment options. However, new therapies are being investigated, including one that

A major leap for biotech in the region is taking place at Masdar City. Insilico Medicine is launching the UAE’s first fully end-to-end drug discovery program for oncology, and it’s all happening within our Life Sciences cluster. bit.ly/3ZgbqUN

The first generative AI drug to get to a Phase 2 randomized clinical trial. The small molecule in pill form, rentosertib, showed signs of efficacy for idiopathic pulmonary fibrosis Nature Medicine Insilico Medicine nature.com/articles/s4159…

Insilico Medicine Eyes Q4 Start for Late-Stage Trials of IPF Candidate The AI drug developer publishes results for rentosertib showing the idiopathic pulmonary fibrosis drug led to improved lung function #bioprocessing #ArtificialIntelligence #LungDisease hubs.li/Q03qqcrq0

ddw-online.com/insilico-medic… Insilico Medicine study validates ENPP1 as immune checkpoint for cancers

Insilico’s IPF drug demonstrated ‘clinically meaningful’ benefits in trial #longevity #biotech #drugdiscovery #AI longevity.technology/news/insilicos…

linkedin.com/posts/zhavoron…

📣 Join Insilico Medicine at the Biotechnology Innovation Organization Convention in Boston! 📍 Booth #489 We’re proud to announce the following presentations from our Leadership team: 🎤 AI in Biopharma: What’s Working and What’s Left to Prove 📅 Monday, June 16 | 🕐

nature.com/articles/s4438… The AI drug revolution needs a revolution Thank you for the mention, nature Nature Portfolio 🤝

See you there

Qiming Venture Partners' portfolio company Insilico Medicine announced the Nature Medicine publication of Phase 2a results for Rentosertib, a novel TNIK inhibitor for idiopathic pulmonary fibrosis, discovered and designed using a pioneering AI-driven approach. insilico.com/tpost/tnrecuxs…